Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 12/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711724 | 0.92 | STAT3 (0.58) | STAT3LMNATDP1TP53 | |
| SCHEMBL2853844 | 0.84 | STAT3 (0.52) | STAT3PTPN11PTPROPDK1 | |
| SCHEMBL2855112 | 0.81 | STAT3 (0.57) | STAT3PTPN11PTPROMEN1KMT2A | |
| SCHEMBL2857060 | 0.81 | STAT3 (0.57) | STAT3PTPN11PTPROHNF4A | |
| SCHEMBL2859069 | 0.80 | PTPN11 (0.50) | STAT3LMNATDP1PTPN11PTPRO | |
| SCHEMBL13711783 | 0.80 | STAT3 (0.68) | STAT3PTPN11PTPROPDK1 | |
| SCHEMBL2855206 | 0.77 | STAT3 (0.54) | STAT3PTPN11PTPROMEN1KMT2A | |
| SCHEMBL2859223 | 0.77 | LMNA (0.43) | LMNATDP1TP53MAPTTHRB | |
| SCHEMBL2853410 | 0.77 | STAT3 (0.60) | STAT3PTPN11PTPROMEN1KMT2A | |
| SCHEMBL2851611 | 0.76 | STAT3 (0.49) | STAT3PTPN11PTPRO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | claimed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | claimed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | claimed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | claimed |
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| EP-1654247-A1 | ALKYNYL ARYL CARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012280-A1 | ALKYNYL ARYL CARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | STAT3 2129/4885LMNA 4710/4885TDP1 875/4885 |
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | STAT3 2684/4885LMNA 2923/4885TDP1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.